Could Elliott Management help drive the GlaxoSmithKline (GSK) share price up?

US activist fund Elliott Management has built a stake in GlaxoSmithKline. Christopher Ruane assesses what that might mean for the GSK share price.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

A GlaxoSmithKline scientist uses a microscope

Image: GlaxoSmithKline

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

sdf

Pharmaceutical giant GlaxoSmithKline (LSE: GSK) has a noisy shareholder. Activist firm Elliott Management has built a multibillion pound stake in the company. Could this be good news for the GSK share price?

I think it could. 

GSK share price weakness

While I like the yield of almost 6%, I find it hard to get excited about the GSK share price. It is down 2% this year, and 21% over the past 12 months. That is hardly the performance of shareholder dreams.

Moreover, even the dividend level might not last. That is a risk for all dividends. But it is specifically a risk for GSK, which plans to split into two entities. It has previously signalled that it expects the combined payout after the split might not add up to as much as the current dividend.

GSK is a blue-chip stock and constituent of the FTSE 100 index. Seeing its recent price weakness has definitely made me wonder whether now is the time to buy the stock.

Enter Elliott

Apparently I am not alone in that thought.

Elliott is a US-based fund manager. It is what is known as an activist fund. In layman’s terms, that means that it does not always just buy shares and quietly wait for the postman to drop dividends through its door. Instead, it seeks to increase the value of some of the companies in which it buys stakes. For example, this can be through putting pressure on management to improve performance or change strategy.

GSK strikes me as a classic target for activist managers right now. The share price has languished. There are concerns about its future pipeline of new drugs not being large enough. But it boasts assets like strong brands, a talented workforce of researchers and an existing distribution network. 

Even just having Elliott on board will likely be good for the GSK share price, in my view. The size of its investment suggests that it means business. 

Where next for the GSK share price

Breaking into two businesses already offered the prospect of revaluation of GSK. I think its attractive stable of consumer brands such as Sensodyne and Panadol may be valued more highly when freed from the corporate structure of a legacy pharmaceutical company.

Elliott’s involvement could also be helping to bolster the share price. And if it does manage to focus management attention and fix the pharma pipeline, I think that will improve the GSK business. That should be positive for the GSK share price further down the line.

Risks

However, there are risks. An antagonistic shareholder can be a distraction for management from running the business. The demerger may not go smoothly, and so destroy instead of create value. The challenge with the pipeline could persist despite investor activism, reducing future revenue streams.

Short-term cost cuts in response to activist pressure can damage companies too. I’ll be keeping an eye on GSK to see exactly what Elliott plans to do with its investment.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

christopherruane has no position in any of the shares mentioned. The Motley Fool UK has recommended GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

A senior man and his wife holding hands walking up a hill on a footpath looking away from the camera at the view. The fishing village of Polperro is behind them.
Investing Articles

3 shares that could help a SIPP double in value

Christopher Ruane discusses a trio of FTSE 100 shares that he thinks investors should consider for their long-term potential to…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

I’ve doubled my money on this growth stock but I’m not selling it any time soon

Uber has been a great investment for Edward Sheldon, rising more than 100% in just two years. He believes the…

Read more »

British union jack flag and Parliament house at city of Westminster in the background
Investing Articles

The FTSE 100 is on fire! Yet these 2 stocks still look cheap to me

Despite the FTSE 100 hitting record highs, there’s no shortage of undervalued opportunities across the index, says Ben McPoland.

Read more »

Female student sitting at the steps and using laptop
Investing Articles

Greggs shares: an outstanding bargain after crashing nearly 40%?

Shares of one-time market darling Greggs have been in foul form recently. But is this a once-in-a-blue-moon opportunity for our…

Read more »

Close-up of children holding a planet at the beach
Investing Articles

This FTSE 100 stock’s suddenly become the highest-yielder on the index!

The league table of FTSE 100 (INDEXFTSE:UKX) dividend stocks has a new number one. But our writer explains why there…

Read more »

Rear View Of Woman Holding Man Hand during travel in cappadocia
Investing Articles

Is this under-the-radar UK stock as cheap as its rooms?

Our writer’s been keeping an eye on a little-known UK stock that operates in a niche, but profitable, sector of…

Read more »

Young Caucasian woman holding up four fingers
Investing Articles

It’s a ‘Fabulous Friday’ for holders of these FTSE 100 shares!

Four members of the FTSE 100 (INDEXFTSE:UKX) are making their latest dividend payments today (11 July). Our writer takes a…

Read more »

Man riding the bus alone
Investing Articles

Check out this spectacular FTSE 250 stock

UK investors willing to look beyond the FTSE 100 can find some outstanding companies. Online advertising business Baltic Classifieds might…

Read more »